Bone Abstracts

Osteogenesis imperfecta is a clinically heterogeneous heritable connective tissue disorder. Most OI cases are due to mutations in type I collagen genes, COL1A1 and COL1A2 encoding the pro-alpha1(I) and pro-alpha2(I) chains respectively. However, genotype–phenotype correlation has not been completely elucidated yet. In this study we evaluated a familial case including a mother and a daughter, classified as OI type I. The daughter had more severe clinical ...

Fibrous dysplasia of bone (FD) is a crippling skeletal disease caused by activating mutations (R201C, R201H) of the Gsα gene. We recently generated GsαR201C transgenic mice that develop a FD skeletal phenotype. The analyses of these mice demonstrated that increased bone resorption is one of the main morbidity factors in FD and that RANKL is the major molecular mediator of osteolysis at affected skeletal sites.Ob...

Introduction: The clinical diagnosis of mild forms of hypophosphatasia [HPP], a rare genetic bone disease, is often made in adulthood, on the basis of persistently low serum levels of alkaline phosphatase [ALP], often coupled with signs of poor bone/teeth mineralization.Case report: A 50-year-old male on treatment with vitamin D supplementation because of osteoporosis of lumbar spine (T-score –3.2) and femoral neck (T-score –2.4), was referred ...

Barrier membranes have been extensively used in dentistry to prevent soft tissue down-growth into the bone defects and to promote alveolar ridge augmentation. Previous studies of our group showed that the Poly(vinylidene-trifluoroethylene)/barium titanate composite (PVDF) enhances both the in vitro osteoblastic differentiation and the in vivo bone repair compared with a commercially available polytetrafluoroethylene (PTFE) membrane. As bone formation may be regulated ...

Objective: To define, by expert consensus, the criteria for the application of a Treat-to-Target (T2T) strategy in osteoporosis, in Spain, and to assess the adequacy of current treatments for it.Material and methods: Six Spanish experts in osteoporosis formed the Scientific Committee that led the project and designed the questionnaire used in two Delphi rounds. The 24 items included in the questionnaire assessed the experts’ wish (W) and prognosis (...

Objective: To define, by expert consensus, the criteria for the application of a Treat-to-Target (T2T) strategy in osteoporosis, in Spain, and to assess the adequacy of current treatments for it.Material and methods: Six Spanish experts in osteoporosis formed the Scientific Committee that led the project and designed the questionnaire used in two Delphi rounds. The 24 items included in the questionnaire assessed the experts’ wish (W) and prognosis (...

Introduction: Gorham disease (GD), also known as Gorham–Stout syndrome, massive osteolysis or disappearing bone disease, is a very rare disease characterized by spontaneous and progressive osteolysis of one or more bones. Its prognosis is highly variable and unpredictable, ranging from minimal disability to death, due to involvement of vital structures, such as the vertebral column and rib cage. Osteoclasts hyperactivity has been suggested as potential pathogenetic abnorm...

Pioglitazone is a drug of the thiazolidinedione (TZD) class used to treat type 2 diabetes mellitus. TZD is an agonist of peroxisome proliferator-activated receptor γ (PPAR-γ) that improves insulin sensitivity, glucose and lipid metabolism and inflammation. However, TZD induces bone marrow adiposity with suppression of osteogenesis, that could contribute to bone loss and osteoporotic fractures. β-Cryptoxanthin is a carotenoid with antioxidant properties abundant ...

Long-term use of pharmacological treatments of osteoporosis is currently a controversial subject within the scientific community.The aim of this work was to study the effects produced by a preventive long duration treatment of strontium ranelate and zoledronic acid on bone mass and remodelling when they are administered to ovariectomized rats.Sixty female albino Wistar rats were divided into four groups (n=15): SHAM group ...

Denosumab (DNMB) is an effective treatment for osteoporosis with antiresorptive effect that has demonstrated to increase the bone mass and reduces the incidence of both vertebral and nonvertebral fractures in randomized controlled trials (RCTs).Objectives: To confirm that this drug is actually effective in our experience into daily clinical practice as well.Material and methods: 30 postmenopausal women, mean age 71 years (r</em...